Drug Interactions between measles virus vaccine / mumps virus vaccine / rubella virus vaccine / varicella virus vaccine and Vitamin D3
This report displays the potential drug interactions for the following 2 drugs:
- measles virus vaccine/mumps virus vaccine/rubella virus vaccine/varicella virus vaccine
- Vitamin D3 (cholecalciferol)
Interactions between your drugs
measles virus vaccine rubella virus vaccine
Applies to: measles virus vaccine / mumps virus vaccine / rubella virus vaccine / varicella virus vaccine and measles virus vaccine / mumps virus vaccine / rubella virus vaccine / varicella virus vaccine
ADJUST DOSING INTERVAL: If multiple live, attenuated parenteral viral or bacterial vaccines are not given on the same day, but are administered within 28 days of each other, the immune response to the second live parenteral vaccine may be diminished by the immune response to the first. The exact mechanism of this interaction is unknown, but may involve competition for cellular receptors, competition for molecular substrates required for replication, and/or induction of inhibitory host proteins like interferon. Clinical data are limited and sometimes conflicting. One randomized clinical trial in Brazil was conducted in 12-month-old children (n=1769) receiving routine vaccinations. Volunteers were randomized to receive simultaneous yellow fever (YF) and measles, mumps, rubella (MMR) vaccines or to receive YF 30 days after the MMR vaccine. Subjects who received both vaccines simultaneously had lower seroconversion rates for rubella, YF, and mumps than those vaccinated 30 days apart (90% vs. 97%, 70% vs. 87%, and 62% vs. 71%, respectively). Seroconversion rates for measles were unaffected (>98% in both groups). Geometric mean titers (GMT) for rubella and YF were approximately three times higher in those who were vaccinated 30 days apart. However, a different randomized, non-inferiority trial in healthy one-year-old children in Argentina (n=738), which evaluated coadministration of MMR and YF vaccines compared to MMR followed by the YF vaccine 28 to 35 days later, or YF followed by the MMR vaccine 28 to 35 days later, reported that effective seroconversion was achieved when the two vaccines were administered concurrently. This study did note that antibody levels for rubella and YF were significantly lower following co-administration. A separate study conducted in two U.S. health maintenance organizations found that the risk for varicella vaccine failure (defined as varicella disease in a vaccinated individual) was three times higher in those who received the varicella vaccine within 28 days of the MMR vaccine, when compared to those who received the varicella vaccine more than 28 days after MMR vaccination. Clinical data are not available for all possible live vaccine combinations in all age groups.
MANAGEMENT: The U.S. Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices generally recommends that doses of live, attenuated parenteral viral or bacterial vaccines that are not administered simultaneously (using different injection sites and separate needles and syringes for injectable products not formulated as combinations) should be separated by an interval of at least 28 days. If the live vaccines involved are separated by less than 4 weeks, the second vaccine administered should not be counted and the dose should be repeated at least 4 weeks later. Oral vaccines (e.g., Ty21a typhoid vaccine and rotavirus) can be administered simultaneously with or at any interval before or after other live vaccines if indicated. The United Kingdom's Green Book recommends always separating the YF and MMR vaccines by at least 4 weeks, unless rapid protection is required in which case they advise considering an additional dose of the MMR vaccine. Additionally, the Canadian Immunization Guide recommends avoiding simultaneous administration of a first-generation smallpox vaccine with a varicella-containing vaccine; suggesting that if both are needed, the varicella-containing vaccine should be given at least 4 weeks before or after the first-generation smallpox vaccine. Current local immunization guidelines and prescribing information for individual vaccines should be consulted for specific recommendations.
References (9)
- Public Health Agency of Canada (2025) Timing of vaccine administration: Canadian Immunization Guide. https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-1-key-immunization-information/page-10-timing-vaccine-administration.html
- US Centers for Disease Control and Prevention (CDC) (2025) Timing and spacing of immunobiologics. https://www.cdc.gov/vaccines/hcp/imz-best-practices/timing-spacing-immunobiologics.html
- Staples JE, O'Laughlin K (2025) Yellow Fever https://www.cdc.gov/yellow-book/hcp/travel-associated-infections-diseases/yellow-fever.html#prevent
- UK Health Security Agency (2025) Contraindications and special considerations: the green book, chapter 6. https://www.gov.uk/government/publications/contraindications-and-special-considerations-the-green-book-chapter-6
- UK Health Security Agency (2025) Measles: the green book, chapter 21. https://www.gov.uk/government/publications/measles-the-green-book-chapter-21
- Australian Government. Department of Health and Aged Care (2025) Preparing for vaccination. https://immunisationhandbook.health.gov.au/contents/vaccination-procedures/preparing-for-vaccination
- Nascimento Silva JR, Camacho LA, Siqueira MM, et al. (2011) "Mutual interference on the immune response to yellow fever vaccine and a combined vaccine against measles, mumps and rubella." Vaccine, 29, p. 6327-34
- Boikos C, Papenburg J, Martineau C, et al. (2017) "Viral interference and the live-attenuated intranasal influenza vaccine: results from a pediatric cohort with cystic fibrosis." Hum Vacc Immunother, 13, p. 1254-60
- Vizzotti C, Harris JB, Aquino A, et al. (2025) Immune response to co-administration of measles, mumps, and rubella (MMR) and yellow fever vaccines: a randomized non-inferiority trial among one-year-old children in Argentina. https://pmc.ncbi.nlm.nih.gov/articles/PMC10021967/
measles virus vaccine mumps virus vaccine
Applies to: measles virus vaccine / mumps virus vaccine / rubella virus vaccine / varicella virus vaccine and measles virus vaccine / mumps virus vaccine / rubella virus vaccine / varicella virus vaccine
ADJUST DOSING INTERVAL: If multiple live, attenuated parenteral viral or bacterial vaccines are not given on the same day, but are administered within 28 days of each other, the immune response to the second live parenteral vaccine may be diminished by the immune response to the first. The exact mechanism of this interaction is unknown, but may involve competition for cellular receptors, competition for molecular substrates required for replication, and/or induction of inhibitory host proteins like interferon. Clinical data are limited and sometimes conflicting. One randomized clinical trial in Brazil was conducted in 12-month-old children (n=1769) receiving routine vaccinations. Volunteers were randomized to receive simultaneous yellow fever (YF) and measles, mumps, rubella (MMR) vaccines or to receive YF 30 days after the MMR vaccine. Subjects who received both vaccines simultaneously had lower seroconversion rates for rubella, YF, and mumps than those vaccinated 30 days apart (90% vs. 97%, 70% vs. 87%, and 62% vs. 71%, respectively). Seroconversion rates for measles were unaffected (>98% in both groups). Geometric mean titers (GMT) for rubella and YF were approximately three times higher in those who were vaccinated 30 days apart. However, a different randomized, non-inferiority trial in healthy one-year-old children in Argentina (n=738), which evaluated coadministration of MMR and YF vaccines compared to MMR followed by the YF vaccine 28 to 35 days later, or YF followed by the MMR vaccine 28 to 35 days later, reported that effective seroconversion was achieved when the two vaccines were administered concurrently. This study did note that antibody levels for rubella and YF were significantly lower following co-administration. A separate study conducted in two U.S. health maintenance organizations found that the risk for varicella vaccine failure (defined as varicella disease in a vaccinated individual) was three times higher in those who received the varicella vaccine within 28 days of the MMR vaccine, when compared to those who received the varicella vaccine more than 28 days after MMR vaccination. Clinical data are not available for all possible live vaccine combinations in all age groups.
MANAGEMENT: The U.S. Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices generally recommends that doses of live, attenuated parenteral viral or bacterial vaccines that are not administered simultaneously (using different injection sites and separate needles and syringes for injectable products not formulated as combinations) should be separated by an interval of at least 28 days. If the live vaccines involved are separated by less than 4 weeks, the second vaccine administered should not be counted and the dose should be repeated at least 4 weeks later. Oral vaccines (e.g., Ty21a typhoid vaccine and rotavirus) can be administered simultaneously with or at any interval before or after other live vaccines if indicated. The United Kingdom's Green Book recommends always separating the YF and MMR vaccines by at least 4 weeks, unless rapid protection is required in which case they advise considering an additional dose of the MMR vaccine. Additionally, the Canadian Immunization Guide recommends avoiding simultaneous administration of a first-generation smallpox vaccine with a varicella-containing vaccine; suggesting that if both are needed, the varicella-containing vaccine should be given at least 4 weeks before or after the first-generation smallpox vaccine. Current local immunization guidelines and prescribing information for individual vaccines should be consulted for specific recommendations.
References (9)
- Public Health Agency of Canada (2025) Timing of vaccine administration: Canadian Immunization Guide. https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-1-key-immunization-information/page-10-timing-vaccine-administration.html
- US Centers for Disease Control and Prevention (CDC) (2025) Timing and spacing of immunobiologics. https://www.cdc.gov/vaccines/hcp/imz-best-practices/timing-spacing-immunobiologics.html
- Staples JE, O'Laughlin K (2025) Yellow Fever https://www.cdc.gov/yellow-book/hcp/travel-associated-infections-diseases/yellow-fever.html#prevent
- UK Health Security Agency (2025) Contraindications and special considerations: the green book, chapter 6. https://www.gov.uk/government/publications/contraindications-and-special-considerations-the-green-book-chapter-6
- UK Health Security Agency (2025) Measles: the green book, chapter 21. https://www.gov.uk/government/publications/measles-the-green-book-chapter-21
- Australian Government. Department of Health and Aged Care (2025) Preparing for vaccination. https://immunisationhandbook.health.gov.au/contents/vaccination-procedures/preparing-for-vaccination
- Nascimento Silva JR, Camacho LA, Siqueira MM, et al. (2011) "Mutual interference on the immune response to yellow fever vaccine and a combined vaccine against measles, mumps and rubella." Vaccine, 29, p. 6327-34
- Boikos C, Papenburg J, Martineau C, et al. (2017) "Viral interference and the live-attenuated intranasal influenza vaccine: results from a pediatric cohort with cystic fibrosis." Hum Vacc Immunother, 13, p. 1254-60
- Vizzotti C, Harris JB, Aquino A, et al. (2025) Immune response to co-administration of measles, mumps, and rubella (MMR) and yellow fever vaccines: a randomized non-inferiority trial among one-year-old children in Argentina. https://pmc.ncbi.nlm.nih.gov/articles/PMC10021967/
measles virus vaccine varicella virus vaccine
Applies to: measles virus vaccine / mumps virus vaccine / rubella virus vaccine / varicella virus vaccine and measles virus vaccine / mumps virus vaccine / rubella virus vaccine / varicella virus vaccine
ADJUST DOSING INTERVAL: If multiple live, attenuated parenteral viral or bacterial vaccines are not given on the same day, but are administered within 28 days of each other, the immune response to the second live parenteral vaccine may be diminished by the immune response to the first. The exact mechanism of this interaction is unknown, but may involve competition for cellular receptors, competition for molecular substrates required for replication, and/or induction of inhibitory host proteins like interferon. Clinical data are limited and sometimes conflicting. One randomized clinical trial in Brazil was conducted in 12-month-old children (n=1769) receiving routine vaccinations. Volunteers were randomized to receive simultaneous yellow fever (YF) and measles, mumps, rubella (MMR) vaccines or to receive YF 30 days after the MMR vaccine. Subjects who received both vaccines simultaneously had lower seroconversion rates for rubella, YF, and mumps than those vaccinated 30 days apart (90% vs. 97%, 70% vs. 87%, and 62% vs. 71%, respectively). Seroconversion rates for measles were unaffected (>98% in both groups). Geometric mean titers (GMT) for rubella and YF were approximately three times higher in those who were vaccinated 30 days apart. However, a different randomized, non-inferiority trial in healthy one-year-old children in Argentina (n=738), which evaluated coadministration of MMR and YF vaccines compared to MMR followed by the YF vaccine 28 to 35 days later, or YF followed by the MMR vaccine 28 to 35 days later, reported that effective seroconversion was achieved when the two vaccines were administered concurrently. This study did note that antibody levels for rubella and YF were significantly lower following co-administration. A separate study conducted in two U.S. health maintenance organizations found that the risk for varicella vaccine failure (defined as varicella disease in a vaccinated individual) was three times higher in those who received the varicella vaccine within 28 days of the MMR vaccine, when compared to those who received the varicella vaccine more than 28 days after MMR vaccination. Clinical data are not available for all possible live vaccine combinations in all age groups.
MANAGEMENT: The U.S. Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices generally recommends that doses of live, attenuated parenteral viral or bacterial vaccines that are not administered simultaneously (using different injection sites and separate needles and syringes for injectable products not formulated as combinations) should be separated by an interval of at least 28 days. If the live vaccines involved are separated by less than 4 weeks, the second vaccine administered should not be counted and the dose should be repeated at least 4 weeks later. Oral vaccines (e.g., Ty21a typhoid vaccine and rotavirus) can be administered simultaneously with or at any interval before or after other live vaccines if indicated. The United Kingdom's Green Book recommends always separating the YF and MMR vaccines by at least 4 weeks, unless rapid protection is required in which case they advise considering an additional dose of the MMR vaccine. Additionally, the Canadian Immunization Guide recommends avoiding simultaneous administration of a first-generation smallpox vaccine with a varicella-containing vaccine; suggesting that if both are needed, the varicella-containing vaccine should be given at least 4 weeks before or after the first-generation smallpox vaccine. Current local immunization guidelines and prescribing information for individual vaccines should be consulted for specific recommendations.
References (9)
- Public Health Agency of Canada (2025) Timing of vaccine administration: Canadian Immunization Guide. https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-1-key-immunization-information/page-10-timing-vaccine-administration.html
- US Centers for Disease Control and Prevention (CDC) (2025) Timing and spacing of immunobiologics. https://www.cdc.gov/vaccines/hcp/imz-best-practices/timing-spacing-immunobiologics.html
- Staples JE, O'Laughlin K (2025) Yellow Fever https://www.cdc.gov/yellow-book/hcp/travel-associated-infections-diseases/yellow-fever.html#prevent
- UK Health Security Agency (2025) Contraindications and special considerations: the green book, chapter 6. https://www.gov.uk/government/publications/contraindications-and-special-considerations-the-green-book-chapter-6
- UK Health Security Agency (2025) Measles: the green book, chapter 21. https://www.gov.uk/government/publications/measles-the-green-book-chapter-21
- Australian Government. Department of Health and Aged Care (2025) Preparing for vaccination. https://immunisationhandbook.health.gov.au/contents/vaccination-procedures/preparing-for-vaccination
- Nascimento Silva JR, Camacho LA, Siqueira MM, et al. (2011) "Mutual interference on the immune response to yellow fever vaccine and a combined vaccine against measles, mumps and rubella." Vaccine, 29, p. 6327-34
- Boikos C, Papenburg J, Martineau C, et al. (2017) "Viral interference and the live-attenuated intranasal influenza vaccine: results from a pediatric cohort with cystic fibrosis." Hum Vacc Immunother, 13, p. 1254-60
- Vizzotti C, Harris JB, Aquino A, et al. (2025) Immune response to co-administration of measles, mumps, and rubella (MMR) and yellow fever vaccines: a randomized non-inferiority trial among one-year-old children in Argentina. https://pmc.ncbi.nlm.nih.gov/articles/PMC10021967/
rubella virus vaccine mumps virus vaccine
Applies to: measles virus vaccine / mumps virus vaccine / rubella virus vaccine / varicella virus vaccine and measles virus vaccine / mumps virus vaccine / rubella virus vaccine / varicella virus vaccine
ADJUST DOSING INTERVAL: If multiple live, attenuated parenteral viral or bacterial vaccines are not given on the same day, but are administered within 28 days of each other, the immune response to the second live parenteral vaccine may be diminished by the immune response to the first. The exact mechanism of this interaction is unknown, but may involve competition for cellular receptors, competition for molecular substrates required for replication, and/or induction of inhibitory host proteins like interferon. Clinical data are limited and sometimes conflicting. One randomized clinical trial in Brazil was conducted in 12-month-old children (n=1769) receiving routine vaccinations. Volunteers were randomized to receive simultaneous yellow fever (YF) and measles, mumps, rubella (MMR) vaccines or to receive YF 30 days after the MMR vaccine. Subjects who received both vaccines simultaneously had lower seroconversion rates for rubella, YF, and mumps than those vaccinated 30 days apart (90% vs. 97%, 70% vs. 87%, and 62% vs. 71%, respectively). Seroconversion rates for measles were unaffected (>98% in both groups). Geometric mean titers (GMT) for rubella and YF were approximately three times higher in those who were vaccinated 30 days apart. However, a different randomized, non-inferiority trial in healthy one-year-old children in Argentina (n=738), which evaluated coadministration of MMR and YF vaccines compared to MMR followed by the YF vaccine 28 to 35 days later, or YF followed by the MMR vaccine 28 to 35 days later, reported that effective seroconversion was achieved when the two vaccines were administered concurrently. This study did note that antibody levels for rubella and YF were significantly lower following co-administration. A separate study conducted in two U.S. health maintenance organizations found that the risk for varicella vaccine failure (defined as varicella disease in a vaccinated individual) was three times higher in those who received the varicella vaccine within 28 days of the MMR vaccine, when compared to those who received the varicella vaccine more than 28 days after MMR vaccination. Clinical data are not available for all possible live vaccine combinations in all age groups.
MANAGEMENT: The U.S. Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices generally recommends that doses of live, attenuated parenteral viral or bacterial vaccines that are not administered simultaneously (using different injection sites and separate needles and syringes for injectable products not formulated as combinations) should be separated by an interval of at least 28 days. If the live vaccines involved are separated by less than 4 weeks, the second vaccine administered should not be counted and the dose should be repeated at least 4 weeks later. Oral vaccines (e.g., Ty21a typhoid vaccine and rotavirus) can be administered simultaneously with or at any interval before or after other live vaccines if indicated. The United Kingdom's Green Book recommends always separating the YF and MMR vaccines by at least 4 weeks, unless rapid protection is required in which case they advise considering an additional dose of the MMR vaccine. Additionally, the Canadian Immunization Guide recommends avoiding simultaneous administration of a first-generation smallpox vaccine with a varicella-containing vaccine; suggesting that if both are needed, the varicella-containing vaccine should be given at least 4 weeks before or after the first-generation smallpox vaccine. Current local immunization guidelines and prescribing information for individual vaccines should be consulted for specific recommendations.
References (9)
- Public Health Agency of Canada (2025) Timing of vaccine administration: Canadian Immunization Guide. https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-1-key-immunization-information/page-10-timing-vaccine-administration.html
- US Centers for Disease Control and Prevention (CDC) (2025) Timing and spacing of immunobiologics. https://www.cdc.gov/vaccines/hcp/imz-best-practices/timing-spacing-immunobiologics.html
- Staples JE, O'Laughlin K (2025) Yellow Fever https://www.cdc.gov/yellow-book/hcp/travel-associated-infections-diseases/yellow-fever.html#prevent
- UK Health Security Agency (2025) Contraindications and special considerations: the green book, chapter 6. https://www.gov.uk/government/publications/contraindications-and-special-considerations-the-green-book-chapter-6
- UK Health Security Agency (2025) Measles: the green book, chapter 21. https://www.gov.uk/government/publications/measles-the-green-book-chapter-21
- Australian Government. Department of Health and Aged Care (2025) Preparing for vaccination. https://immunisationhandbook.health.gov.au/contents/vaccination-procedures/preparing-for-vaccination
- Nascimento Silva JR, Camacho LA, Siqueira MM, et al. (2011) "Mutual interference on the immune response to yellow fever vaccine and a combined vaccine against measles, mumps and rubella." Vaccine, 29, p. 6327-34
- Boikos C, Papenburg J, Martineau C, et al. (2017) "Viral interference and the live-attenuated intranasal influenza vaccine: results from a pediatric cohort with cystic fibrosis." Hum Vacc Immunother, 13, p. 1254-60
- Vizzotti C, Harris JB, Aquino A, et al. (2025) Immune response to co-administration of measles, mumps, and rubella (MMR) and yellow fever vaccines: a randomized non-inferiority trial among one-year-old children in Argentina. https://pmc.ncbi.nlm.nih.gov/articles/PMC10021967/
rubella virus vaccine varicella virus vaccine
Applies to: measles virus vaccine / mumps virus vaccine / rubella virus vaccine / varicella virus vaccine and measles virus vaccine / mumps virus vaccine / rubella virus vaccine / varicella virus vaccine
ADJUST DOSING INTERVAL: If multiple live, attenuated parenteral viral or bacterial vaccines are not given on the same day, but are administered within 28 days of each other, the immune response to the second live parenteral vaccine may be diminished by the immune response to the first. The exact mechanism of this interaction is unknown, but may involve competition for cellular receptors, competition for molecular substrates required for replication, and/or induction of inhibitory host proteins like interferon. Clinical data are limited and sometimes conflicting. One randomized clinical trial in Brazil was conducted in 12-month-old children (n=1769) receiving routine vaccinations. Volunteers were randomized to receive simultaneous yellow fever (YF) and measles, mumps, rubella (MMR) vaccines or to receive YF 30 days after the MMR vaccine. Subjects who received both vaccines simultaneously had lower seroconversion rates for rubella, YF, and mumps than those vaccinated 30 days apart (90% vs. 97%, 70% vs. 87%, and 62% vs. 71%, respectively). Seroconversion rates for measles were unaffected (>98% in both groups). Geometric mean titers (GMT) for rubella and YF were approximately three times higher in those who were vaccinated 30 days apart. However, a different randomized, non-inferiority trial in healthy one-year-old children in Argentina (n=738), which evaluated coadministration of MMR and YF vaccines compared to MMR followed by the YF vaccine 28 to 35 days later, or YF followed by the MMR vaccine 28 to 35 days later, reported that effective seroconversion was achieved when the two vaccines were administered concurrently. This study did note that antibody levels for rubella and YF were significantly lower following co-administration. A separate study conducted in two U.S. health maintenance organizations found that the risk for varicella vaccine failure (defined as varicella disease in a vaccinated individual) was three times higher in those who received the varicella vaccine within 28 days of the MMR vaccine, when compared to those who received the varicella vaccine more than 28 days after MMR vaccination. Clinical data are not available for all possible live vaccine combinations in all age groups.
MANAGEMENT: The U.S. Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices generally recommends that doses of live, attenuated parenteral viral or bacterial vaccines that are not administered simultaneously (using different injection sites and separate needles and syringes for injectable products not formulated as combinations) should be separated by an interval of at least 28 days. If the live vaccines involved are separated by less than 4 weeks, the second vaccine administered should not be counted and the dose should be repeated at least 4 weeks later. Oral vaccines (e.g., Ty21a typhoid vaccine and rotavirus) can be administered simultaneously with or at any interval before or after other live vaccines if indicated. The United Kingdom's Green Book recommends always separating the YF and MMR vaccines by at least 4 weeks, unless rapid protection is required in which case they advise considering an additional dose of the MMR vaccine. Additionally, the Canadian Immunization Guide recommends avoiding simultaneous administration of a first-generation smallpox vaccine with a varicella-containing vaccine; suggesting that if both are needed, the varicella-containing vaccine should be given at least 4 weeks before or after the first-generation smallpox vaccine. Current local immunization guidelines and prescribing information for individual vaccines should be consulted for specific recommendations.
References (9)
- Public Health Agency of Canada (2025) Timing of vaccine administration: Canadian Immunization Guide. https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-1-key-immunization-information/page-10-timing-vaccine-administration.html
- US Centers for Disease Control and Prevention (CDC) (2025) Timing and spacing of immunobiologics. https://www.cdc.gov/vaccines/hcp/imz-best-practices/timing-spacing-immunobiologics.html
- Staples JE, O'Laughlin K (2025) Yellow Fever https://www.cdc.gov/yellow-book/hcp/travel-associated-infections-diseases/yellow-fever.html#prevent
- UK Health Security Agency (2025) Contraindications and special considerations: the green book, chapter 6. https://www.gov.uk/government/publications/contraindications-and-special-considerations-the-green-book-chapter-6
- UK Health Security Agency (2025) Measles: the green book, chapter 21. https://www.gov.uk/government/publications/measles-the-green-book-chapter-21
- Australian Government. Department of Health and Aged Care (2025) Preparing for vaccination. https://immunisationhandbook.health.gov.au/contents/vaccination-procedures/preparing-for-vaccination
- Nascimento Silva JR, Camacho LA, Siqueira MM, et al. (2011) "Mutual interference on the immune response to yellow fever vaccine and a combined vaccine against measles, mumps and rubella." Vaccine, 29, p. 6327-34
- Boikos C, Papenburg J, Martineau C, et al. (2017) "Viral interference and the live-attenuated intranasal influenza vaccine: results from a pediatric cohort with cystic fibrosis." Hum Vacc Immunother, 13, p. 1254-60
- Vizzotti C, Harris JB, Aquino A, et al. (2025) Immune response to co-administration of measles, mumps, and rubella (MMR) and yellow fever vaccines: a randomized non-inferiority trial among one-year-old children in Argentina. https://pmc.ncbi.nlm.nih.gov/articles/PMC10021967/
mumps virus vaccine varicella virus vaccine
Applies to: measles virus vaccine / mumps virus vaccine / rubella virus vaccine / varicella virus vaccine and measles virus vaccine / mumps virus vaccine / rubella virus vaccine / varicella virus vaccine
ADJUST DOSING INTERVAL: If multiple live, attenuated parenteral viral or bacterial vaccines are not given on the same day, but are administered within 28 days of each other, the immune response to the second live parenteral vaccine may be diminished by the immune response to the first. The exact mechanism of this interaction is unknown, but may involve competition for cellular receptors, competition for molecular substrates required for replication, and/or induction of inhibitory host proteins like interferon. Clinical data are limited and sometimes conflicting. One randomized clinical trial in Brazil was conducted in 12-month-old children (n=1769) receiving routine vaccinations. Volunteers were randomized to receive simultaneous yellow fever (YF) and measles, mumps, rubella (MMR) vaccines or to receive YF 30 days after the MMR vaccine. Subjects who received both vaccines simultaneously had lower seroconversion rates for rubella, YF, and mumps than those vaccinated 30 days apart (90% vs. 97%, 70% vs. 87%, and 62% vs. 71%, respectively). Seroconversion rates for measles were unaffected (>98% in both groups). Geometric mean titers (GMT) for rubella and YF were approximately three times higher in those who were vaccinated 30 days apart. However, a different randomized, non-inferiority trial in healthy one-year-old children in Argentina (n=738), which evaluated coadministration of MMR and YF vaccines compared to MMR followed by the YF vaccine 28 to 35 days later, or YF followed by the MMR vaccine 28 to 35 days later, reported that effective seroconversion was achieved when the two vaccines were administered concurrently. This study did note that antibody levels for rubella and YF were significantly lower following co-administration. A separate study conducted in two U.S. health maintenance organizations found that the risk for varicella vaccine failure (defined as varicella disease in a vaccinated individual) was three times higher in those who received the varicella vaccine within 28 days of the MMR vaccine, when compared to those who received the varicella vaccine more than 28 days after MMR vaccination. Clinical data are not available for all possible live vaccine combinations in all age groups.
MANAGEMENT: The U.S. Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices generally recommends that doses of live, attenuated parenteral viral or bacterial vaccines that are not administered simultaneously (using different injection sites and separate needles and syringes for injectable products not formulated as combinations) should be separated by an interval of at least 28 days. If the live vaccines involved are separated by less than 4 weeks, the second vaccine administered should not be counted and the dose should be repeated at least 4 weeks later. Oral vaccines (e.g., Ty21a typhoid vaccine and rotavirus) can be administered simultaneously with or at any interval before or after other live vaccines if indicated. The United Kingdom's Green Book recommends always separating the YF and MMR vaccines by at least 4 weeks, unless rapid protection is required in which case they advise considering an additional dose of the MMR vaccine. Additionally, the Canadian Immunization Guide recommends avoiding simultaneous administration of a first-generation smallpox vaccine with a varicella-containing vaccine; suggesting that if both are needed, the varicella-containing vaccine should be given at least 4 weeks before or after the first-generation smallpox vaccine. Current local immunization guidelines and prescribing information for individual vaccines should be consulted for specific recommendations.
References (9)
- Public Health Agency of Canada (2025) Timing of vaccine administration: Canadian Immunization Guide. https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-1-key-immunization-information/page-10-timing-vaccine-administration.html
- US Centers for Disease Control and Prevention (CDC) (2025) Timing and spacing of immunobiologics. https://www.cdc.gov/vaccines/hcp/imz-best-practices/timing-spacing-immunobiologics.html
- Staples JE, O'Laughlin K (2025) Yellow Fever https://www.cdc.gov/yellow-book/hcp/travel-associated-infections-diseases/yellow-fever.html#prevent
- UK Health Security Agency (2025) Contraindications and special considerations: the green book, chapter 6. https://www.gov.uk/government/publications/contraindications-and-special-considerations-the-green-book-chapter-6
- UK Health Security Agency (2025) Measles: the green book, chapter 21. https://www.gov.uk/government/publications/measles-the-green-book-chapter-21
- Australian Government. Department of Health and Aged Care (2025) Preparing for vaccination. https://immunisationhandbook.health.gov.au/contents/vaccination-procedures/preparing-for-vaccination
- Nascimento Silva JR, Camacho LA, Siqueira MM, et al. (2011) "Mutual interference on the immune response to yellow fever vaccine and a combined vaccine against measles, mumps and rubella." Vaccine, 29, p. 6327-34
- Boikos C, Papenburg J, Martineau C, et al. (2017) "Viral interference and the live-attenuated intranasal influenza vaccine: results from a pediatric cohort with cystic fibrosis." Hum Vacc Immunother, 13, p. 1254-60
- Vizzotti C, Harris JB, Aquino A, et al. (2025) Immune response to co-administration of measles, mumps, and rubella (MMR) and yellow fever vaccines: a randomized non-inferiority trial among one-year-old children in Argentina. https://pmc.ncbi.nlm.nih.gov/articles/PMC10021967/
Drug and food interactions
cholecalciferol food
Applies to: Vitamin D3 (cholecalciferol)
MONITOR: Additive effects and possible toxicity (e.g., hypercalcemia, hypercalciuria, and/or hyperphosphatemia) may occur when patients using vitamin D and/or vitamin D analogs ingest a diet high in vitamin D, calcium, and/or phosphorus. The biologically active forms of vitamin D stimulate intestinal absorption of calcium and phosphorus. This may be helpful in patients with hypocalcemia and/or hypophosphatemia. However, sudden increases in calcium or phosphorus consumption due to dietary changes could precipitate hypercalcemia and/or hyperphosphatemia. Patients with certain disease states, such as impaired renal function, may be more susceptible to toxic side effects like ectopic calcification. On the other hand, if dietary calcium is inadequate for the body's needs, the active form of vitamin D will stimulate osteoclasts to pull calcium from the bones. This may be detrimental in a patient with reduced bone density.
MANAGEMENT: Given the narrow therapeutic index of vitamin D and vitamin D analogs, the amounts of calcium, phosphorus, and vitamin D present in the patient's diet may need to be taken into consideration. Specific dietary guidance should be discussed with the patient and regular lab work should be monitored as indicated. Calcium, phosphorus, and vitamin D levels should be kept within the desired ranges, which may differ depending on the patient's condition. Patients should also be counseled on the signs and symptoms of hypervitaminosis D, hypercalcemia, and/or hyperphosphatemia.
References (10)
- (2023) "Product Information. Drisdol (ergocalciferol)." Validus Pharmaceuticals LLC
- (2024) "Product Information. Fultium-D3 (colecalciferol)." Internis Pharmaceuticals Ltd
- (2024) "Product Information. Ostelin Specialist Range Vitamin D (colecalciferol)." Sanofi-Aventis Healthcare Pty Ltd T/A Sanofi Consumer Healthcare
- (2021) "Product Information. Rocaltrol (calcitriol)." Atnahs Pharma UK Ltd
- (2019) "Product Information. Calcitriol (calcitriol)." Strides Pharma Inc.
- (2024) "Product Information. Calcitriol (GenRx) (calcitriol)." Apotex Pty Ltd
- (2022) "Product Information. Ergocalciferol (ergocalciferol)." RPH Pharmaceuticals AB
- (2020) "Product Information. Sandoz D (cholecalciferol)." Sandoz Canada Incorporated
- Fischer V, Haffner-Luntzer M, Prystaz K, et al. (2024) Calcium and vitamin-D deficiency marginally impairs fracture healing but aggravates posttraumatic bone loss in osteoporotic mice. https://www.nature.com/articles/s41598-017-07511-2
- National Institutes of Health Office of Dietary Supplements (2024) Vitamin D https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional/#h37
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.